Telo Genomics Corp. (TELO.V)
| Previous Close | 0.1800 |
| Open | 0.1700 |
| Bid | 0.1800 x 0 |
| Ask | 0.2000 x 0 |
| Day's Range | 0.1700 - 0.1800 |
| 52 Week Range | 0.1050 - 0.3350 |
| Volume | |
| Avg. Volume | 30,323 |
| Market Cap | 12.836M |
| Beta (5Y Monthly) | 1.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0500 |
| Earnings Date | May 18, 2024 - May 22, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileTelo Genomics Receives Accreditation from College of American Pathologists
Toronto, Ontario--(Newsfile Corp. - April 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to TELO's laboratory at the MaRS Center in Toronto, Canada; this is based on
NewsfileTelo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial
Toronto, Ontario--(Newsfile Corp. - April 2, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that patient recruitment for its minimal residual disease ("MRD") clinical trial has been initiated, with several patient samples received and processed to date. Also, due to institu
NewsfileTelo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients
Toronto, Ontario--(Newsfile Corp. - February 13, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has received the first patient sample for its clinical trial monitoring multiple myeloma ("MM") disease progression in post-treated patients. The study is being conducted in collaboration with McGill University and the Jewish General Hospital in Montreal, Canada. The trial is listed on the website of the National Library of ...
